Good Health Can’t Wait.

More documents

Recommendations

Info

Good Health Can’t Wait. Dr. Reddy’s Laboratories Limited NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.7: FIXED ASSETS DESCRIPTION Tangible assets AS AT 1 APRIL 2014 GROSS BLOCK DEPRECIATION / AMORTISATION / IMPAIRMENT NET BLOCK ADDITIONS DELETIONS AS AT 31 MARCH 2015 AS AT 1 APRIL 2014 FOR THE YEAR IMPAIRMENT DELETIONS AS AT 31 MARCH 2015 AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 Land 1,256 6 - 1,262 - - - - - 1,262 1,256 Buildings 11,176 1,151 33 12,294 1,966 443 - 17 2,392 9,902 9,210 Plant and machinery 24,218 5,442 806 28,854 12,310 2,648 - 691 14,267 14,587 11,908 Electrical equipment 3,555 1,127 7 4,675 1,783 417 - 6 2,194 2,481 1,772 Laboratory equipment 4,429 797 146 5,080 2,498 465 - 99 2,864 2,216 1,931 Furniture and fixtures 861 63 23 901 591 96 - 20 667 234 270 Office equipment 1,776 334 107 2,003 1,233 275 - 85 1,423 580 543 Vehicles Owned 176 14 44 146 145 22 - 44 123 23 31 Leased 34 1 - 35 18 8 - - 26 9 16 Total tangible assets (A) 47,481 8,935 1,166 55,250 20,544 4,374 - 962 23,956 31,294 26,937 Previous year 40,702 7,547 768 47,481 17,347 3,720 - 523 20,544 26,937 Intangible assets Customer contracts 243 - - 243 243 - - - 243 - - Technical know how 459 11 - 470 459 - - - 459 11 - Product related intangible 631 1,164 - 1,795 85 504 208 - 797 998 546 Copyrights and patents (including marketing / 183 - - 183 183 - - - 183 - - distribution rights) Others - 215 - 215 - 24 - - 24 191 - Total intangible assets (B) 1,516 1,390 - 2,906 970 528 208 - 1,706 1,200 546 Previous year 1,628 202 314 1,516 1,113 85 - 228 970 546 Total (A+B) 48,997 10,325 1,166 58,156 21,514 4,902 208 962 25,662 32,494 27,483 Previous year 42,330 7,749 1,082 48,997 18,460 3,805 - 751 21,514 27,483 Note: a) Depreciation and amortisation for the year includes an amount of ` 478 (previous year: ` 409) pertaining to assets used for research and development. During the year, Company incurred ` 689 (previous year: ` 724) towards capital expenditure for research and development. (Refer note 2.40) b) The Company has capitalised borrowing cost of ` 31 (previous year: ` 77) during the year ended 31 March 2015. c) Additions to intangible assets includes an amount of ` 1,093 paid to DRL Impex Limited, a wholly owned subsidiary of the Company, for acquisition of certain product related intangibles. d) Based on the performance of and expected cash flows from some of the product related intangibles, the Company reassessed the recoverable amounts of such intangibles and determined that their carrying amount was higher than the recoverable amount. Accordingly, an amount of ` 208 was recorded as an impairment loss during the year ended 31 March 2015 under “Other expenses”. 128
Standalone Financial Statements Annual Report 2014 - 15 NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.8: NON CURRENT INVESTMENTS PARTICULARS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 Non current investments at cost I. Quoted investments Equity shares (fully paid-up) 120,000 (previous year: 12,000) equity shares of ` 1/- (previous year: ` 10/-) each of State Bank of India (a) 3 3 Total quoted non current investments ( I ) 3 3 II. Unquoted investments Trade In subsidiary companies Equity shares (fully paid-up) 105,640,410 (previous year: 105,640,410 ) ordinary shares of CHF 1 each of Dr. Reddy’s Laboratories SA, Switzerland 13,515 13,515 2,377,826 (previous year: 2,377,826) equity shares of ` 10/- each of Idea2Enterprises India Private Limited, India 1,447 1,447 90,544,104 (previous year: 90,544,104) equity shares of ` 10/- each of Aurigene Discovery Technologies Limited, India 974 974 140,526,270 (previous year: 140,526,270) Series “A” shares of Peso 1 each of Industrias Quimicas Falcon de Mexico S.A. de C.V., Mexico 709 709 26,699,230 (previous year: 26,699,230) shares of Real $ 1 each of Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil 634 634 9,066,000 (previous year: 9,066,000) ordinary shares of Euro 1 each of Reddy Pharma Iberia SA, Spain 566 566 54,022,070 (previous year: 34,022,070) equity shares of ` 10/- each of Dr. Reddy’s Bio-sciences Limited, India 466 266 1,131,646 (previous year: 1,131,646) equity shares of US $ 1 each of Reddy Antilles N.V., Netherlands 52 52 2,500 (previous year: 2,500) ordinary shares of FF 100 each of Reddy Cheminor S.A., France 2 2 134,513 (previous year: 134,513) equity shares of ` 10/- each of Cheminor Investments Limited, India 1 1 50,000 (previous year: 50,000) equity shares of ` 1/- each of Dr. Reddy’s Pharma SEZ Limited, India 1 1 50,000 (previous year: 50,000) equity shares of ` 10/- each of DRL Impex Limited, India 1 1 18,368 18,168 Less: Provision for decline, other than temporary, in the value of non current investments: Reddy Pharma Iberia SA, Spain (566) (566) Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil (634) (634) Total unquoted trade investments in equity shares of subsidiary companies, net (A) 17,168 16,968 In joint venture Equity shares held in Kunshan Rotam Reddy Pharmaceutical Co. Limited, China (b) 429 429 26,000 (previous year: Nil) equity shares of ` 10/- each of DRSS Solar Power Private Limited (c) - - Total unquoted trade investments in equity shares of joint venture companies (B) 429 429 129
Page 1 and 2:
ANNUAL REPORT 2014-15 Good Health C
Page 3 and 4:
Our Brand We are in the business of
Page 5 and 6:
Corporate Overview Annual Report 20
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Statutory Reports • Business Resp
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Statutory Reports • Management Di
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Statutory Reports • Corporate Gov
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Statutory Reports • Additional Sh
Page 75 and 76:
Page 77 and 78:
Page 79 and 80: Statutory Reports • Additional Sh
Page 87 and 88: Statutory Reports • Board’s Rep
Page 111 and 112: Standalone Financial Statements Ann
Page 129: Standalone Financial Statements Ann
Page 165 and 166: Consolidated Financial Statements A
Page 181 and 182:
Consolidated Financial Statements A
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Notice Annual Report 2014 - 15 NOTI
Page 229 and 230:
E-Voting Annual Report 2014 - 15 IN
Page 231:
Dr. Reddy’s Laboratories Limited
Page 235 and 236:
The future belongs, not to those wh
show all

Good Health Can’t Wait.

Create successful ePaper yourself

Delete template?

Save as template?